Project Orbis is a global initiative that aims to streamline regulatory review processes across international regulators in the USA, Canada, Australia, UK, Israel, Brazil, Singapore, and Switzerland to bring promising cancer drugs to patients earlier. We explored the clinical benefit, time to regulatory approval and health technology assessment recommendations, reimbursement outcomes, and monthly treatment prices of cancer drugs reviewed through this initiative.

中文翻译：

---

在美国、加拿大、英格兰和苏格兰通过 Orbis 项目审查的 FDA 批准的癌症药物的临床益处、报销结果和价格：回顾性比较分析


Orbis 项目是一项全球计划，旨在简化美国、加拿大、澳大利亚、英国、以色列、巴西、新加坡和瑞士国际监管机构的监管审查流程，以更早地为患者带来有前景的癌症药物。我们探讨了通过该计划审查的癌症药物的临床益处、监管批准时间和卫生技术评估建议、报销结果和每月治疗价格。